ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases
- 13 August 2024
- Vol. 56 (7) , 961-968
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Commission of Shanghai Municipality (21ZR1440100)
- National Natural Science Foundation of China (82300212ce)
This publication has 37 references indexed in Scilit:
- Primary ALK-Positive Large B Cell Lymphoma of PancreasJournal of Gastrointestinal Cancer, 2021
- Diffuse large B-cell lymphoma variants: an updatePathology, 2020
- Loss of 5-Hydroxymethylcytosine Is an Epigenetic Biomarker in Cutaneous T-Cell LymphomaJournal of Investigative Dermatology, 2018
- ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining patternInternational Journal of Hematology, 2016
- Identification of RANBP2–ALK fusion in ALK positive diffuse large B‐cell lymphomaHematological Oncology, 2014
- ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangementsLaboratory Investigation, 2013
- Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of MelanomaCell, 2012
- Anaplastic lymphoma kinase–positive large B-cell lymphoma with complex karyotype and novel ALK gene rearrangementsHuman Pathology, 2011
- Hyperactivated STAT3 in ALK–positive diffuse large B-cell lymphoma with clathrin-ALK fusionHuman Pathology, 2009
- ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangementHuman Pathology, 2004